Last reviewed · How we verify
Placebo females
Placebo produces no pharmacological effect and works through the placebo effect, where patient expectation and clinical context influence symptom perception and outcomes.
Placebo produces no pharmacological effect and works through the placebo effect, where patient expectation and clinical context influence symptom perception and outcomes. Used for Clinical trial control arm (not a therapeutic indication).
At a glance
| Generic name | Placebo females |
|---|---|
| Also known as | Saline physiological 5 ml |
| Sponsor | Ullevaal University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance or sham intervention that lacks active pharmaceutical ingredients. Its therapeutic effects, when observed, arise from psychological and neurobiological mechanisms including expectation, conditioning, and the therapeutic context rather than direct drug action. Placebo is commonly used as a control in clinical trials to establish the efficacy of active treatments.
Approved indications
- Clinical trial control arm (not a therapeutic indication)
Common side effects
- Nocebo effects (adverse events attributed to placebo expectation)
Key clinical trials
- Efficacy of Nigella Sativa (Nisatol®) in Women With Borderline Blood Pressure Values or a Non-Dipper Blood Pressure Phenotype (NA)
- Menopausal Hormones and Sympathetic Activation (PHASE4)
- The Effects of Commercially Available High Protein Drink on Amino Acid Bioavailability and Recovery From Muscle Fatiguing Exercise in 18-45-year-old Male and Female Participants. (NA)
- Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate (NA)
- The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists (PHASE1)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea (PHASE2)
- Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |